脑细胞保护研究最高优先事项——范式转变:STAIR XI报告
STAIR XI工作组提出用「脑细胞保护」替代「神经保护」以涵盖全脑获益,并提出「组织窗」选择再通患者及「靶窗」概念指导神经血管单元分时靶向治疗。工作组更新了临床前推荐,分为探索性资格验证与确定性验证两阶段,强调作用机制、药代/药效、靶点结合与血脑屏障穿透表征,并建议采用雌雄动物及考虑年龄合并症的多中心协作测试。
要点
- 建议以「脑细胞保护」替代「神经保护」,反映全脑获益意图
- 组织窗可依据影像选择再通患者,不限于症状发作时间
- 靶窗概念强调神经血管单元不同成分在不同时间窗的差异化靶向
核心结论
- STAIR XI提出将「神经保护」改称「脑细胞保护」或「脑保护」,以表明候选治疗使整个大脑获益。
- 提出「组织窗」用于选择再通患者,以及「靶窗」用于指导神经血管单元不同成分的分时靶向治疗。
- 在缺乏公认脑细胞保护金标准的前提下,全面临床前评估能否有效预测临床结局仍属推测。
研究设计与样本
- STAIR XI第1工作组「神经保护最高优先事项」基于共识提出建议,重新定义神经保护范式并更新临床前推荐。
- 临床前推荐分为两阶段:探索性资格验证阶段与确定性验证阶段。
主要发现
- 组织成像技术可识别预测核心梗死与半暗带可挽救组织的患者,不受卒中症状发作后时间限制。
- 神经血管单元各成分在不同脑区以不同时间尺度呈现差异化易损性。
- 候选治疗临床前测试建议使用雌雄两种性别动物,并纳入年龄与合并症等重要变量。
关键数值与推荐
- 对新型候选治疗,研究者应仔细表征作用机制、药代动力学/药效动力学、证明靶点结合并确认血脑屏障穿透。
- 临床前评估可采用多中心协作测试(如网络试验)以全面方式进行。
临床怎么用
- 临床选择再通患者时可依据组织窗影像而非仅依赖时间窗。
- 开发脑细胞保护治疗时应按两阶段临床前框架系统评估机制、药代/药效、靶点结合与血脑屏障穿透。
局限性
- 原文指出,在缺乏已证明的脑细胞保护剂作为金标准的情况下,全面临床前评估能否有效预测临床结局仍属推测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite years of basic research and pioneering clinical work, ischemic stroke remains a major public health concern. Prior STAIR (Stroke Treatment Academic Industry Roundtable) conferences identified both failures of clinical trial design and failures in preclinical assessment in developing putative ischemic stroke treatments. At STAIR XI, participants in workshop no. 1 Top Priorities for Neuroprotection sought to redefine the neuroprotection paradigm and given the paucity of evidence underlying preclinical assessment, offer consensus-based recommendations. STAIR proposes the term brain cytoprotection or cerebroprotection to replace the term neuroprotection when the intention of an investigation is to demonstrate that a new, candidate treatment benefits the entire brain. Although "time is still brain," tissue imaging techniques have been developed to identify patients with both predicted core injury and penumbral, salvageable brain tissue, regardless of time after stroke symptom onset. STAIR XI workshop participants called this imaging approach a tissue window to select patients for recanalization. Elements of the neurovascular unit show differential vulnerability evolving over differing time scales in different brain regions. STAIR proposes the term target window to suggest therapies that target the different elements of the neurovascular unit at different times. Based on contemporary principles of rigor and transparency, the workshop updated, revised, and enhanced the STAIR preclinical recommendations for developing new treatments in 2 phases: an exploratory qualification phase and a definitive validation phase. For new, putative treatments, investigators should carefully characterize the mechanism of action, the pharmacokinetics/pharmacodynamics, demonstrate target engagement, and confirm penetration through the blood-brain barrier. Before clinical trials, testing of candidate molecules in stroke models could proceed in a comprehensive manner using animals of both sexes and to include significant variables such as age and comorbid conditions. Comprehensive preclinical assessment might include multicenter, collaborative testing, for example, network trials. In the absence of a proven cerebroprotective agent to use as a gold standard, however, it remains speculative whether such comprehensive preclinical assessment can effectively predict clinical outcome.
引用
- Lyden P, Buchan A, Boltze J, et al. Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI. Stroke. 2021. PMID: 34289707. doi:10.1161/STROKEAHA.121.034947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。